...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.
【24h】

Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer.

机译：他莫昔芬或阿那曲唑对绝经后乳腺癌女性类固醇硫酸酯酶活性和血清雄激素浓度的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: In postmenopausal women estrogens can be formed by the aromatase pathway, which gives rise to estrone, and the steroid sulfatase (STS) route which can result in the formation of estrogens and androstenediol, a steroid with potent estrogenic properties. Aromatase inhibitors, such as anastrozole, are now in clinical use whereas STS inhibitors, such as STX64, are still undergoing clinical evaluation. STX64 was recently shown to block STS activity and reduce serum androstenediol concentrations in postmenopausal women with breast cancer. In contrast, little is known about the effects of aromatase inhibitors or anti-estrogens on STS activity or serum androgen levels. PATIENTS AND METHODS: Study 1: Blood was collected from ten postmenopausal women with breast cancer before and after two-week treatment with anastrozole and serum concentrations of androstenediol and other androgens and estrogens were assessed. Study 2: Blood samples were collected from 15 breast cancer patients before and after four-week treatment with anastrozole and 10 patients before and after four-week treatment with tamoxifen. Blood was used to assess STS activity in peripheral blood lymphocytes (PBLs) and serum dehydroepiandrosterone sulfate and dehydroepiandrosterone levels. RESULTS: Neither anastrozole nor tamoxifen had any significant effect on STS activity as measured in PBLs. Anastrozole did not affect serum androstenediol concentrations. CONCLUSION: Anastrozole and tamoxifen did not inhibit STS activity and serum androstenediol concentrations were not reduced by aromatase inhibition. As androstenediol has estrogenic properties, it is possible that the combination of an aromatase inhibitor and STS inhibitor may give a therapeutic advantage over the use of either agent alone.
机译：背景：在绝经后的女性中，雌激素可以通过芳香酶途径（产生雌酮）和类固醇硫酸酯酶（STS）途径形成，后者可以导致雌激素和雄烯二醇的形成，这是一种具有强大雌激素特性的类固醇。芳香酶抑制剂（例如阿那曲唑）现已投入临床使用，而STS抑制剂（例如STX64）仍在进行临床评估。最近显示STX64可以阻断绝经后乳腺癌女性的STS活性并降低其血清雄甾烯二醇的浓度。相反，关于芳香酶抑制剂或抗雌激素对STS活性或血清雄激素水平的影响知之甚少。病人和方法：研究1：在十个绝经后的乳腺癌患者使用阿那曲唑治疗两周之前和之后收集血液，并评估了雄烯二醇和其他雄激素和雌激素的血清浓度。研究2：分别从15名乳腺癌患者接受阿那曲唑治疗4周之前和之后以及10名患者接受他莫昔芬治疗前后血液样本。血液用于评估外周血淋巴细胞（PBL）中的STS活性以及血清硫酸脱氢表雄酮和脱氢表雄酮的水平。结果：阿那曲唑和他莫昔芬均未对PTS中的STS活性产生任何显着影响。阿那曲唑不影响血清雄烯二醇浓度。结论：阿那曲唑和他莫昔芬不能抑制STS活性，并且芳香化酶抑制作用不会降低血清中雄甾烯二醇的浓度。由于雄烯二醇具有雌激素特性，与单独使用任何一种试剂相比，芳香酶抑制剂和STS抑制剂的组合可能具有治疗优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号